IL6 and congenital rubella syndrome: Evidence from preclinical mouse models42 has demonstrated the importance of IL‐1β43 and IL‐644 in the pathophysiology of CRS, and the benefit of IL‐1 receptor and IL‐6 blockade in ameliorating CRS.